Sonoma Pharmaceuticals Inc (SNOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has a cash flow conversion efficiency ratio of -0.223x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-764.00K) by net assets ($3.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sonoma Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.
Sonoma Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sonoma Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Sonoma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TMM REAL EST.DEV.GDR S 1
F:TR61
|
N/A |
|
Casa Minerals Inc
V:CASA
|
0.040x |
|
Knosys Ltd
AU:KNO
|
-0.200x |
|
Biotron Ltd
AU:BIT
|
-0.322x |
|
Xpon Technologies Group Ltd
AU:XPN
|
-1.594x |
|
SThree plc
LSE:STEM
|
0.183x |
|
Chijet Motor Company, Inc. Ordinary Shares
NASDAQ:CJET
|
-0.010x |
|
STRIP TINNING HLDG.LS-01
F:VH3
|
N/A |
Annual Cash Flow Conversion Efficiency for Sonoma Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Sonoma Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.41 Million | $-88.00K | -0.020x | +94.89% |
| 2024-03-31 | $6.14 Million | $-2.40 Million | -0.391x | +49.33% |
| 2023-03-31 | $7.98 Million | $-6.15 Million | -0.771x | -57.89% |
| 2022-03-31 | $8.70 Million | $-4.25 Million | -0.488x | +22.45% |
| 2021-03-31 | $5.36 Million | $-3.38 Million | -0.630x | +22.84% |
| 2020-03-31 | $5.62 Million | $-4.59 Million | -0.816x | +26.92% |
| 2019-03-31 | $10.49 Million | $-11.72 Million | -1.117x | -37.63% |
| 2018-03-31 | $15.33 Million | $-12.44 Million | -0.812x | -112.98% |
| 2017-03-31 | $21.43 Million | $-8.17 Million | -0.381x | +55.82% |
| 2016-03-31 | $10.14 Million | $-8.75 Million | -0.863x | -55.32% |
| 2015-03-31 | $12.05 Million | $-6.69 Million | -0.555x | -36.99% |
| 2014-03-31 | $12.06 Million | $-4.89 Million | -0.405x | -243.85% |
| 2013-03-31 | $4.08 Million | $1.15 Million | 0.282x | -93.93% |
| 2012-03-31 | $-868.00K | $-4.03 Million | 4.645x | +278.40% |
| 2011-03-31 | $1.70 Million | $-4.43 Million | -2.604x | -176.30% |
| 2010-03-31 | $7.04 Million | $-6.64 Million | -0.942x | +87.30% |
| 2009-03-31 | $2.27 Million | $-16.83 Million | -7.418x | -556.02% |
| 2008-03-31 | $15.43 Million | $-17.45 Million | -1.131x | +6.81% |
| 2007-03-31 | $14.90 Million | $-18.08 Million | -1.213x | +56.61% |
| 2006-03-31 | $7.34 Million | $-20.52 Million | -2.796x | +54.50% |
| 2005-03-31 | $2.20 Million | $-13.53 Million | -6.146x | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more